CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PMV Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PMV Pharmaceuticals Inc
One Research Way
Phone: (609) 642-6664p:609 642-6664 PRINCETON, NJ  08540  United States Ticker: PMVPPMVP
Business Summary
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard A.Heyman 65 6/1/2020 6/1/2020
President, Chief Executive Officer, Co-Founder, Director David H.Mack 61 7/1/2013 6/1/2013
Chief Financial Officer, Principal Accounting Officer MichaelCarulli 50 1/5/2024 1/5/2024
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 63 (As of 12/31/2023)
Outstanding Shares: 51,443,488 (As of 2/28/2024)
Shareholders: 7
Stock Exchange: NASD
Federal Tax Id: 463218129
Fax Number: (302) 636-5454
Email Address: info@pmvpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024